Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment

Immune checkpoint inhibitors (ICIs) targeting PD-L1 and PD-1 have improved survival in a subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a minority of NSCLC patients respond to ICIs, highlighting the need for superior immunotherapy. Herein, we report on a nanoparti...

Descripción completa

Detalles Bibliográficos
Autores principales: Reda, Moataz, Ngamcherdtrakul, Worapol, Nelson, Molly A., Siriwon, Natnaree, Wang, Ruijie, Zaidan, Husam Y., Bejan, Daniel S., Reda, Sherif, Hoang, Ngoc Ha, Crumrine, Noah A., Rehwaldt, Justin P. C., Bindal, Akash, Mills, Gordon B., Gray, Joe W., Yantasee, Wassana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308817/
https://www.ncbi.nlm.nih.gov/pubmed/35871223
http://dx.doi.org/10.1038/s41467-022-31926-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308817/
https://www.ncbi.nlm.nih.gov/pubmed/35871223
http://dx.doi.org/10.1038/s41467-022-31926-9

Ejemplares similares